Advertisement

Molecular Neurobiology

, Volume 42, Issue 1, pp 64–75 | Cite as

The Role of Mitochondria in Glioma Pathophysiology

  • Bartlomiej B. Ordys
  • Séverine Launay
  • Ruth F. Deighton
  • James McCulloch
  • Ian R. Whittle
Article

Abstract

It has long been recognised that malignant tumours favour aerobic glycolysis to generate ATP and contain abnormalities of the intrinsic, mitochondria-dependent, apoptotic pathway, suggesting the involvement of dysfunctional mitochondria in tumour pathophysiology. However, the mechanisms underlying such processes in gliomas are poorly understood. Few recent studies have evaluated mitochondrial ultrastructure and proteomics in the pathophysiology of malignant gliomas. However, aberrant energy metabolism has been reported in gliomas and mitochondrial dysfunction links to glioma apoptotic signalling have been observed. Mitochondrial structural abnormalities and dysfunction in malignant gliomas is a neglected area of research. Definition of abnormalities in mitochondrial proteomics, membrane potential regulation, energy metabolism and intrinsic apoptotic pathway signalling in gliomas may open novel therapeutic opportunities.

Keyword

Mitochondria Glioma Apoptosis Pathophysiology Mitochondrial dysfunction Cell death 

References

  1. 1.
    Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS (1999) Cancer surveillance series: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382–1390PubMedGoogle Scholar
  2. 2.
    Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278–299PubMedGoogle Scholar
  3. 3.
    DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123PubMedGoogle Scholar
  4. 4.
    Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT (1995) The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 37:67–73PubMedGoogle Scholar
  5. 5.
    Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8–31PubMedGoogle Scholar
  6. 6.
    Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710PubMedGoogle Scholar
  7. 7.
    Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J, Auvinen A (2007) Incidence of gliomas by anatomic location. Neuro Oncol 9:319–325PubMedGoogle Scholar
  8. 8.
    Inskip PD, Linet MS, Heineman EF (1995) Etiology of brain tumors in adults. Epidemiol Rev 17:382–414PubMedGoogle Scholar
  9. 9.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC, LyonGoogle Scholar
  10. 10.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedGoogle Scholar
  11. 11.
    Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430–446PubMedGoogle Scholar
  12. 12.
    Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899PubMedGoogle Scholar
  13. 13.
    Anderson E, Grant R, Lewis SC, Whittle IR (2004) Randomized phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg (2008) 22:339–349Google Scholar
  14. 14.
    Glioma Meta-Analysis Trialists (GMT) Group (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018Google Scholar
  15. 15.
    Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493–500PubMedGoogle Scholar
  16. 16.
    Seyfried TN, Mukherjee P (2005) Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab 2:30Google Scholar
  17. 17.
    Benard G, Rossignol R (2008) Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid Redox Signal 10:1313–1342PubMedGoogle Scholar
  18. 18.
    Nicholls DG, Budd SL (2000) Mitochondria and neuronal survival. Physiol Rev 80:315–360PubMedGoogle Scholar
  19. 19.
    Hertz L, Peng L, Dienel GA (2007) Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metab 27:219–249PubMedGoogle Scholar
  20. 20.
    Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr (1967) Brain metabolism during fasting. J Clin Invest 46:1589–1595PubMedGoogle Scholar
  21. 21.
    Pellerin L, Bergersen LH, Halestrap AP, Pierre K (2005) Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 79:55–64PubMedGoogle Scholar
  22. 22.
    Froberg MK, Gerhart DZ, Enerson BE, Manivel C, Guzman-Paz M, Seacotte N, Drewes LR (2001) Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport 12:761–765PubMedGoogle Scholar
  23. 23.
    Cahill GF Jr (2006) Fuel metabolism in starvation. Annu Rev Nutr 26:1–22PubMedGoogle Scholar
  24. 24.
    Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr (2001) Ketone bodies, potential therapeutic uses. IUBMB Life 51:241–247PubMedGoogle Scholar
  25. 25.
    Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P (2003) Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89:1375–1382PubMedGoogle Scholar
  26. 26.
    Galarraga J, Loreck DJ, Graham JF, DeLaPaz RL, Smith BH, Hallgren D, Cummins CJ (1986) Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1:279–291PubMedGoogle Scholar
  27. 27.
    Roslin M, Henriksson R, Bergström P, Ungerstedt U, Bergenheim AT (2003) Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61:151–160PubMedGoogle Scholar
  28. 28.
    Williams ZR, Goodman CB, Soliman KF (2007) Anaerobic glycolysis protection against 1-methy-4-phenylpyridinium (MPP+) toxicity in C6 glioma cells. Neurochem Res 32:1071–1080PubMedGoogle Scholar
  29. 29.
    Warburg O (ed) (1931) The metabolism of tumours. Richard R. Smith, New YorkGoogle Scholar
  30. 30.
    Roeder LM, Poduslo SE, Tildon JT (1982) Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res 8:671–682PubMedGoogle Scholar
  31. 31.
    Patel MS, Russell JJ, Gershman H (1981) Ketone-body metabolism in glioma and neuroblastoma cells. Proc Natl Acad Sci U S A 78:7214–7218PubMedGoogle Scholar
  32. 32.
    Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab 4:5Google Scholar
  33. 33.
    Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14:202–208PubMedGoogle Scholar
  34. 34.
    Mukherjee P, Abate LE, Seyfried TN (2004) Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10:5622–5629PubMedGoogle Scholar
  35. 35.
    Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN (2002) Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 86:1615–1621PubMedGoogle Scholar
  36. 36.
    Andersson AK, Rönnbäck L, Hansson E (2005) Lactate induces tumour necrosis factor-alpha, interleukin-6 and interleukin-1beta release in microglial- and astroglial-enriched primary cultures. J Neurochem 93:1327–1333PubMedGoogle Scholar
  37. 37.
    Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899PubMedGoogle Scholar
  38. 38.
    Schlame M, Rua D, Greenberg ML (2000) The biosynthesis and functional role of cardiolipin. Prog Lipid Res 39:257–288PubMedGoogle Scholar
  39. 39.
    Ardail D, Privat JP, Egret-Charlier M, Levrat C, Lerme F, Louisot P (1990) Mitochondrial contact sites. Lipid composition and dynamics. J Biol Chem 265:18797–18802PubMedGoogle Scholar
  40. 40.
    LeCcocq J, Ballou CE (1964) On the structure of cardiolipin. Biochemistry 3:976–980Google Scholar
  41. 41.
    Schlame M, Brody S, Hostetler KY (1993) Mitochondrial cardiolipin in diverse eukaryotes. Comparison of biosynthetic reactions and molecular acyl species. Eur J Biochem 212:727–735PubMedGoogle Scholar
  42. 42.
    Schlame M, Hostetler KY (1997) Cardiolipin synthase from mammalian mitochondria. Biochim Biophys Acta 1348:207–213PubMedGoogle Scholar
  43. 43.
    Fry M, Green DE (1981) Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J Biol Chem 256:1874–1880PubMedGoogle Scholar
  44. 44.
    Robinson NC, Zborowski J, Talbert LH (1990) Cardiolipin-depleted bovine heart cytochrome c oxidase: binding stoichiometry and affinity for cardiolipin derivatives. Biochemistry 29:8962–8969PubMedGoogle Scholar
  45. 45.
    Robinson NC (1993) Functional binding of cardiolipin to cytochrome c oxidase. J Bioenerg Biomembr 25:153–163PubMedGoogle Scholar
  46. 46.
    Eble KS, Coleman WB, Hantgan RR, Cunningham CC (1990) Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy. J Biol Chem 265:19434–19440PubMedGoogle Scholar
  47. 47.
    Beyer K, Klingenberg M (1985) ADP/ATP carrier protein from beef heart mitochondria has high amounts of tightly bound cardiolipin, as revealed by 31P nuclear magnetic resonance. Biochemistry 24:3821–3826PubMedGoogle Scholar
  48. 48.
    Hoffmann B, Stöckl A, Schlame M, Beyer K, Klingenberg M (1994) The reconstituted ADP/ATP carrier activity has an absolute requirement for cardiolipin as shown in cysteine mutants. J Biol Chem 269:1940–1944PubMedGoogle Scholar
  49. 49.
    Bogdanov M, Mileykovskaya E, Dowhan W (2008) Lipids in the assembly of membrane proteins and organization of protein supercomplexes: implications for lipid-linked disorders. Subcell Biochem 49:197–239PubMedGoogle Scholar
  50. 50.
    Jiang F, Ryan MT, Schlame M, Zhao M, Gu Z, Klingenberg M, Pfanner N, Greenberg ML (2000) Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem 275:22387–22394PubMedGoogle Scholar
  51. 51.
    Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN (2008) Brain mitochondrial lipid abnormalities in mice susceptible to spontaneous gliomas. Lipids 43:951–959PubMedGoogle Scholar
  52. 52.
    Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN (2008) Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res 49:2545–2556PubMedGoogle Scholar
  53. 53.
    Poli G, Leonarduzzi G, Biasi F, Chiarpotto E (2004) Oxidative stress and cell signalling. Curr Med Chem 11:1163–1182PubMedGoogle Scholar
  54. 54.
    Lee HC, Wei YH (2005) Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol 37:822–834PubMedGoogle Scholar
  55. 55.
    Almeida A, Delgado-Esteban M, Bolaños JP, Medina JM (2002) Oxygen and glucose deprivation induces mitochondrial dysfunction and oxidative stress in neurones but not in astrocytes in primary culture. J Neurochem 81:207–217PubMedGoogle Scholar
  56. 56.
    Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME, Roca P (2008) Differences in mitochondrial function and antioxidant systems between regions of human glioma. Cell Physiol Biochem 22:757–768PubMedGoogle Scholar
  57. 57.
    Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA (2006) Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res 4:319–330PubMedGoogle Scholar
  58. 58.
    Petrosillo G, Ruggiero FM, Di Venosa N, Paradies G (2003) Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin. FASEB J 17:714–716PubMedGoogle Scholar
  59. 59.
    Petrosillo G, Di Venosa N, Ruggiero FM, Pistolese M, D’Agostino D, Tiravanti E, Fiore T, Paradies G (2005) Mitochondrial dysfunction associated with cardiac ischemia/reperfusion can be attenuated by oxygen tension control. Role of oxygen-free radicals and cardiolipin. Biochim Biophys Acta 1710:78–86PubMedGoogle Scholar
  60. 60.
    Petrosillo G, Portincasa P, Grattagliano I, Casanova G, Matera M, Ruggiero FM, Ferri D, Paradies G (2007) Mitochondrial dysfunction in rat with nonalcoholic fatty liver involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 1767:1260–1267PubMedGoogle Scholar
  61. 61.
    Degterev A, Boyce M, Yuan J (2003) A decade of caspases. Oncogene 22:8543–8567PubMedGoogle Scholar
  62. 62.
    Klein S, McCormick F, Levitzki A (2005) Killing time for cancer cells. Nat Rev Cancer 5:573–580PubMedGoogle Scholar
  63. 63.
    Frank S, Köhler U, Schackert G, Schackert HK (1999) Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 257:454–459PubMedGoogle Scholar
  64. 64.
    Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, Hollema H, den Dunnen WF (2006) TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 78:161–171PubMedGoogle Scholar
  65. 65.
    Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162–1170PubMedGoogle Scholar
  66. 66.
    Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233–243PubMedGoogle Scholar
  67. 67.
    Panner A, James CD, Berger MS, Pieper RO (2005) mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25:8809–8823PubMedGoogle Scholar
  68. 68.
    O’Neill J, Manion M, Schwartz P, Hockenbery DM (2004) Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim Biophys Acta 1705:43–51PubMedGoogle Scholar
  69. 69.
    Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99–163PubMedGoogle Scholar
  70. 70.
    Zoratti M, Szabò I (1995) The mitochondrial permeability transition. Biochim Biophys Acta 1241:139–176PubMedGoogle Scholar
  71. 71.
    Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55:822–831PubMedGoogle Scholar
  72. 72.
    Gaiser T, Becker MR, Meyer J, Habel A, Siegelin MD (2009) p53-mediated inhibition of angiogenesis in diffuse low-grade astrocytomas. Neurochem Int 54:458–463PubMedGoogle Scholar
  73. 73.
    Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633–2643PubMedGoogle Scholar
  74. 74.
    Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC (1997) Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150:805–814PubMedGoogle Scholar
  75. 75.
    Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J (1994) bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88:520–526PubMedGoogle Scholar
  76. 76.
    Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67:763–768PubMedGoogle Scholar
  77. 77.
    Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M (2002) BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 56:43–49PubMedGoogle Scholar
  78. 78.
    Jiang Z, Zheng X, Rich KM (2003) Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84:273–281PubMedGoogle Scholar
  79. 79.
    Zhu CJ, Li YB, Wong MC (2003) Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J Neurosci Res 74:60–66PubMedGoogle Scholar
  80. 80.
    Guensberg P, Wacheck V, Lucas T, Monia B, Pehamberger H, Eichler HG, Jansen B (2002) Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 48:189–195PubMedGoogle Scholar
  81. 81.
    Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L (2007) BCL-2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21:98–111PubMedGoogle Scholar
  82. 82.
    Wagenknecht B, Glaser T, Naumann U, Kügler S, Isenmann S, Bähr M, Korneluk R, Liston P, Weller M (1999) Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ 6:370–376PubMedGoogle Scholar
  83. 83.
    Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T (1999) A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun 264:847–854PubMedGoogle Scholar
  84. 84.
    Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808–815PubMedGoogle Scholar
  85. 85.
    Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S (2005) Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65:10502–10513PubMedGoogle Scholar
  86. 86.
    Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG (2004) A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305:1471–1474PubMedGoogle Scholar
  87. 87.
    Letai A (2006) Growth factor withdrawal and apoptosis: the middle game. Mol Cell 21:728–730PubMedGoogle Scholar
  88. 88.
    Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206PubMedGoogle Scholar
  89. 89.
    Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144–147PubMedGoogle Scholar
  90. 90.
    Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553PubMedGoogle Scholar
  91. 91.
    Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nistér M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219PubMedGoogle Scholar
  92. 92.
    Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100:13513–13518PubMedGoogle Scholar
  93. 93.
    Knobbe CB, Reifenberger G (2003) Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13:507–518PubMedCrossRefGoogle Scholar
  94. 94.
    Knobbe CB, Trampe-Kieslich A, Reifenberger G (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31:486–490PubMedGoogle Scholar
  95. 95.
    Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256PubMedGoogle Scholar
  96. 96.
    Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87:99–163PubMedGoogle Scholar
  97. 97.
    Cartron PF, Gallenne T, Bougras G, Gautier F, Manero F, Vusio P, Meflah K, Vallette FM, Juin P (2004) The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 16:807–818PubMedGoogle Scholar
  98. 98.
    Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111:331–342PubMedGoogle Scholar
  99. 99.
    Breckenridge DG, Xue D (2004) Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr Opin Cell Biol 16:647–652PubMedGoogle Scholar
  100. 100.
    Lutter M, Fang M, Luo X, Nishijima M, Xie X, Wang X (2000) Cardiolipin provides specificity for targeting of tBid to mitochondria. Nat Cell Biol 2:754–761PubMedGoogle Scholar
  101. 101.
    Lutter M, Perkins GA, Wang X (2001) The pro-apoptotic Bcl-2 family member tBid localizes to mitochondrial contact sites. BMC Cell Biol 2:22PubMedGoogle Scholar
  102. 102.
    Kim TH, Zhao Y, Ding WX, Shin JN, He X, Seo YW, Chen J, Rabinowich H, Amoscato AA, Yin XM (2004) Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome C release. Mol Biol Cell 15:3061–3072PubMedGoogle Scholar
  103. 103.
    Garcia Fernandez M, Troiano L, Moretti L, Nasi M, Pinti M, Salvioli S, Dobrucki J, Cossarizza A (2002) Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ 13:449–455PubMedGoogle Scholar
  104. 104.
    Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, Kini V, Vlasova II, Zhao Q, Zou M, Di P, Svistunenko DA, Kurnikov IV, Borisenko GG (2005) Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 1:223–232PubMedGoogle Scholar
  105. 105.
    Chelli B, Lena A, Vanacore R, Da Pozzo E, Costa B, Rossi L, Salvetti A, Scatena F, Ceruti S, Abbracchio MP, Gremigni V, Martini C (2004) Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol 68:125–134PubMedGoogle Scholar
  106. 106.
    Miettinen H, Kononen J, Haapasalo H, Helén P, Sallinen P, Harjuntausta T, Helin H, Alho H (1995) Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 55:2691–2695PubMedGoogle Scholar
  107. 107.
    Lena A, Rechichi M, Salvetti A, Bartoli B, Vecchio D, Scarcelli V, Amoroso R, Benvenuti L, Gagliardi R, Gremigni V, Rossi L (2009) Drugs targeting the mitochondrial pore act as citotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med 7:13PubMedGoogle Scholar
  108. 108.
    Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E, Marín-Hernández A, Gallardo-Pérez JC (2009) The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35:209–225PubMedGoogle Scholar
  109. 109.
    Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598–608PubMedGoogle Scholar
  110. 110.
    Cuezva JM, Ortega AD, Willers I, Sánchez-Cenizo L, Aldea M, Sánchez-Aragó M (2009) The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta 1792:1145–1158PubMedGoogle Scholar
  111. 111.
    Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511–515PubMedGoogle Scholar
  112. 112.
    Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126–1132PubMedGoogle Scholar
  113. 113.
    Berridge MV, Herst PM, Lawen A (2009) Targeting mitochondrial permeability in cancer drug development. Mol Nutr Food Res 53:76–86PubMedGoogle Scholar
  114. 114.
    Gogvadze V, Zhivotovsky B (2007) Alteration of mitochondrial function and cell sensitization to death. J Bioenerg Biomembr 39:23–30PubMedGoogle Scholar
  115. 115.
    Kiebish MA, Seyfried TN (2005) Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer 5:102PubMedGoogle Scholar
  116. 116.
    Deighton RF, Mcgregor R, Kemp J, Mcculloch J, Whittle IR (2010) Glioma pathophysiology: insights emerging from proteomics. Brain Pathol (in press)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Bartlomiej B. Ordys
    • 1
  • Séverine Launay
    • 2
  • Ruth F. Deighton
    • 2
  • James McCulloch
    • 2
  • Ian R. Whittle
    • 1
  1. 1.Department of Clinical Neurosciences, Western General HospitalUniversity of EdinburghEdinburghUK
  2. 2.Centre for Cognitive and Neural SystemsUniversity of EdinburghEdinburghUK

Personalised recommendations